Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Cancer Research
|
October 22, 2024
SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma
Brianna R Daley, Nancy E Sealover, Bridget A Finniff, et al.
Oncotarget
|
March 18, 2020
Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis
Stefanie Schlager, Carina Salomon, Sabine Olt, et al.
Cell Reports. Medicine
|
November 2, 2024
Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma
Michelangelo Marasco, Dinesh Kumar, Tessa Seale, et al.
Cell Reports. Medicine
|
August 26, 2025
Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer models
Ksenija Slavic Obradovic, Florian Ebner, Artem V Artemov, et al.
Cancer Discovery
|
September 9, 2024
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
Birgit Wilding, Lydia Woelflingseder, Anke Baum, et al.
Biorxiv : the Preprint Server for Biology
|
February 7, 2023
Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
Cancer Discovery
|
August 21, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H Hofmann, Michael Gmachl, Juergen Ramharter, et al.
Nature Cancer
|
August 5, 2024
Co-targeting SOS1 enhances the antitumor effects of KRAS<sup>G12C</sup> inhibitors by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Nature Cancer
|
July 26, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling
Birgit Wilding, Dirk Scharn, Dietrich Böse, et al.
Cell Reports
|
September 21, 2017
Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
Nina Kerres, Steffen Steurer, Stefanie Schlager, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Cancer Research
|
October 22, 2024
SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma
Brianna R Daley, Nancy E Sealover, Bridget A Finniff, et al.
Oncotarget
|
March 18, 2020
Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis
Stefanie Schlager, Carina Salomon, Sabine Olt, et al.
Cell Reports. Medicine
|
November 2, 2024
Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma
Michelangelo Marasco, Dinesh Kumar, Tessa Seale, et al.
Cell Reports. Medicine
|
August 26, 2025
Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer models
Ksenija Slavic Obradovic, Florian Ebner, Artem V Artemov, et al.
Cancer Discovery
|
September 9, 2024
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
Birgit Wilding, Lydia Woelflingseder, Anke Baum, et al.
Biorxiv : the Preprint Server for Biology
|
February 7, 2023
Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
Cancer Discovery
|
August 21, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H Hofmann, Michael Gmachl, Juergen Ramharter, et al.
Nature Cancer
|
August 5, 2024
Co-targeting SOS1 enhances the antitumor effects of KRAS<sup>G12C</sup> inhibitors by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Nature Cancer
|
July 26, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling
Birgit Wilding, Dirk Scharn, Dietrich Böse, et al.
Cell Reports
|
September 21, 2017
Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
Nina Kerres, Steffen Steurer, Stefanie Schlager, et al.
Page
of 5